

BD Physioject™ Disposable Autoinjector



BD Physioject™ Disposable Autoinjector

BD Physioject



270M+

BD Physioject™ Disposable Autoinjector sub-systems manufactured since launch™



10+ Chronic illnesses treated with biologics administered with the BD Physioject™ Disposable Autoinjector



15+ Pharmaceutical companies using the BD Physioject™
Disposable Autoinjector for the development and commercialization of combination products



9+ Drugs launched by pharmaceutical companies in the BD Physioject™ Disposable Autoinjector



>99.99%
System functional
performance reliability
demonstrated for
the BD Physioject™
Disposable Autoinjector²⁺



9 human factors studies conducted (7 Formative, 2 Summative)^{3,4,5}



118M+ BD Physioject™ Disposable Autoinjector sold since launch for

commercial use1



600+ individuals
participated in the
BD Physioject™Disposable
Autoinjector human
factor studies³,4,5

10+ years

since first regulatory approval and supporting the delivery of medications in global markets⁶



8 regions where the BD Physioject[™] Disposable Autoinjector is used with approved medications**

Supportive documentation provided to our partners includes

- Customer product specifications
- Customer drawings
- BD Design Verification Summary Report
- Biocompatibility statement
- Materials of concern and safety information
- Intended use and residual risk information
- Final assembly recommendation

- BD Physioject[™] Disposable Autoinjector validated directions for use (DFU)
- Human Factors summary document
- List of machine manufacturers for final assembly
- Summary of test methods for incoming inspection
- Letter or Authorization (LOA)/ technical dossier

Contact your sales rep or visit bd.com/physioject for more information

BD Medical

Pharmaceutical Systems
<u>United States</u>

1 Becton Drive Franklin Lakes, NJ 07417

+1 800 225 3310

Europe

11 rue Aristide-Bergès 38800 Le Pont-de-Claix

Phone: +33 4 76 68 36 36 - Fax: +33 4 76 68 35 05 Becton Dickinson France S.A.S - Share capital: 64 719 915 € RCS Grenoble B 056 501 711

- * Since 2010** Such as; EU, United States, Russia, Canada, Japan, Argentina, and India
- † When combined with the BD Hypak $^{\!\scriptscriptstyle{T\!M}}$ for Biotech Glass Prefillable Syringe

References and notes

- 1. BD WW Demand Database, 2012-2021
- $2. \ BD \ Quality \ System \ complaint \ data Complaint \ extract \ for \ reported \ user \ complaints \ related \ to \ system \ integration$
- Berteau, Cecile, et al. "Evaluation of performance, safety, subject acceptance, and compliance of a disposable autoinjector for subcutaneous injections in healthy volunteers." Patient Preference and Adherence. 2010:4 379-388
- Schwarzenbach, Florence, et al. "Results of a human factors experiment of the usability and patient acceptance of a new autoinjector in patients with rheumatoid arthritis." Patient Preference and Adherence. 2014:8 199-209
- 5. Summary Report BD Physioject Formative Evaluations (CHFIN 21-31)
- 6. Press Release: October, 2010



bd.com